NANOVEU LIMITED (NVU)

The suspension of trading in the securities of Nanoveu Limited will be lifted immediately following the release by NVU of an announcement regarding a material acquisition and capital raising.

The company releases its Semiconductor System-On-A-Chip (SoC) Presentation

The company has agreed to acquire 100% of Embedded A.I. Systems Pte. Ltd's shares, a semiconductor system on a Chip business and intellectual property portfolio. This acquisition marks a significant milestone in Nanoveu's strategic growth, integrating EMASS's advanced SoC technology into the EyeFly3DTM platform.

The securities of Nanoveu Limited will be suspended from quotation immediately under Listing Rule 17.3. The securities will remain suspended until NVU finalises the announcement referred to in its request for trading halt dated 11 October 2024.

The suspension of trading in the securities of Nanoveu Limited will be lifted immediately, following the release by NVU of an announcement regarding a capital raising.

The company releases a notice of proposed issue of securities.

The Company has secured firm commitments from sophisticated and professional investors in an oversubscribed placement to raise $2.25m via the issuance of 85,576,923 fully paid ordinary shares at $0.026 per share. In addition, the New Shares will be issued with attaching options on a 1-for-1 basis, exercisable at $0.05 before, 31 December 2026.

The securities of Nanoveu Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NVU, pending the release of an announcement regarding a capital raising.

The suspension of trading in the securities of Nanovue Limited will be lifted from the commencement of trading on Wednesday, 10 April 2024 following lodgement of its annual report and release of an announcement regarding the outcome of the Company's application to the Supreme Court of Western Australia seeking orders in relation to the Company's inadvertent error to lodge a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) in relation to the issue of 58,500,000 Shares on 27 January 2023.

The company releases its Corporate Governance Statement.

The company lodges an Appendix 4G.

The company lodges its Annual Report to shareholders.

There has been a delay in the lodgement of its Annual Report for the financial year ended 31 December 2023. The delay is to allow the Company's auditor, BDO Audit (WA) Pty Ltd, time to finalise itsreview. While the Company had anticipated that this would be finalised to allow for the release of its annual report by 28 March 2024, there have been delays resulting from unforeseen circumstances. The Company is in discussions with ASX regarding its financial position. Shareholders can expect those discussions to continue in the lead up to the Company releasing its Annual Report for FY2023 (expected in the week commencing 1 April 2024). Until those discussions have been resolved, the Company's securities will remain suspended from trading.

The Company is in discussions with ASX regarding its financial position. Shareholders can expect those discussions to continue next week in the lead up to the Company releasing its Annual Report for FY23 (expected by 28 March 2024). Until those discussions have been resolved, the Company's securities will remain suspended from trading

At the hearing earlier today, the Court made the orders sought by the Company, namely: that in relation to the Share Issues, pursuant to section 1322(4)(d) of the Corporations Act, the period of five business days referred to in section 708A(6)(a) of the Corporations Act be extended to 7 March 2024; that in relation to the Share Issues, pursuant to section 1322(4)(a) of the Corporations Act, it is declared that each notice under section 708A(5)(e) of the Corporations Act given to ASX on 7 March 2024 be deemed to take effect as if it had been given to ASX on the respective issue dates of the Share Issue; in relation to the shares issued on 27 January 2023 and 30 January 2023, pursuant to section 1322(4) of the Corporations Act, it is declared that any offer for sale or sale of those shares during the period after their respective issue to the date of the Court order is not invalid by reason of any failure of a notice under section 708A(5)(e) of the Corporations Act to exempt the sellers from the obligations of disclosure under the Corporations Act, and the seller's consequent failure to comply with section 707(3) of the Corporations Act; in relation to the Half Year Report, pursuant to section 1322 (4)(d) of the Corporations Act, the period by which the Half Year Report must be lodged with the ASIC referred to in section 320(1) of the Corporations Act be extended to 4 December 2023.

The Company has made an application to the Supreme Court of Western Australia seeking orders in relation to: three inadvertent administrative errors whereby the Company failed to lodge a cleansing notice in strict compliance with the requirements of sections 708A(5)(e) of the Corporations Act 2001 (Cth) in connection with the issue of shares on 27 January 2023, 30 January 2023 and 20 June 2023; and its failure to lodge the 30 June 2023 half year report with the Australian Securities and Investments Commission by the date required in section 320(1) of the Corporations Act. The Application is scheduled to be heard by the Supreme Court of Western Australia at 11:00am on Tuesday 19 March 2024. The Company lodged its Half Year Report on 4 December 2023.

The company releases an Appendix 2A.

The company releases a cleansing notice.

The company releases an Appendix 3G.

The company releases a notification of cessation of securities.

The company lodges its Preliminary Final Report.

The company releases a notification regarding unquoted securities.

The company releases a notice of application for quotation of securities.

The company releases a notification regarding unquoted securities.

The company releases a notice of application for quotation of securities.

The company lodges its Quarterly Appendix 4C Cash Flow Report.

The company lodges its Quarterly Activities Report.

The company releases a notice of proposed issue of securities.

The Company has received firm commitments from existing sophisticated and professional investors to raise $600,000 (before costs) through the placement of 35,294,117 fully paid ordinary shares in the Company at an issue price of $0.017 per Share, together with 1 free attaching unquoted option (exercisable at $0.025 expiring 36 months from the issue date of the Placement Share) for every 1 Placement Share issued. Nanoveu will repay an existing unsecured and interest free loan of $150,000 with Sixty Two via the issue Placement Shares and Placement Options on the same terms as the Placement. The Company will issue 8,823,529 Placement Shares and 8,823,529 Placement Options pursuant to the Company's placement capacity under ASX Listing Rule 7.1.

The company lodges its Quarterly Activities Report.

The company lodges its Quarterly Appendix 4C Cash Flow Report.

The company lodges its Half Yearly Report and Accounts.

Purchase orders received from Rahum Nanotech Co. Ltd for US$223,000 (AUD $350,110) to develop EyeFly3DTM products for the latest range of Smartphones. Purchase Order calls for Nanoveu to develop a universal base mould for imprinted lenses that can enable glasses-free 3D experiences on OLED based smartphones. Nanoveu to develop unique software (APP) and products that leverage Nanoveu's EyeFly3D technology to support the display of Rahum visual content in 3D without the need for glasses. Rahum's sales to target major phone brands like iPhone and Samsung, with plans to expand sales beyond South Korea.

Nanoshield Solar boosted power output an average 25.4% compared to untreated solar panel controls over a 72 hour observation period. Results demonstrate tremendous potential of NanoshieldTM Solar range to increase power output efficiency, particularly for aged installations > 10 years old. Succesful demonstration expected to support US commercialisation efforts starting with the Southeast US solar markets.

The company releases a response to the ASX Query.

The company lodges its Quarterly Activities Report.

The company lodges its Quarterly Appendix 4C Cash Flow Report.

The securities of Nanoveu Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NVU, pending the release of an announcement regarding the outcome of the Company's intended application to the Supreme Court of Western Australia seeking orders in relation to the Company's inadvertent error to lodge a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) in relation to the issue of 58,500,000 Shares on 27 January 2023.

The suspension of trading in the securities of Nanoveu Limited will be lifted from the commencement of trading on Friday, 14 August 2020, following the release by NVU of an announcement regarding a capital raising.

The company releases a notice of Proposed issue of Securities - NVU.

Nanoveu has secured an up to $2,400,000 investment by Antiviral Technologies Portfolio, LLC, a US based specialist institutional investor. An initial investment of $600,000 on execution. An additional $1,000,000 to be invested subject to shareholders' approval ($400,000 at the Investor's election). A further $800,000 may be invested by mutual consent of both parties subject to shareholders' approval. Funds will strengthen Nanoveu's balance sheet ahead of launch of new business lines including antiviral screen protector technology and laminating machines.

The securities of Nanoveu Limited will be suspended from quotation from the commencement of normal trading on Friday, 7 August 2020 under Listing Rule 17.2, at the request of NVU, pending the release of an announcement regarding a capital raising.

The suspension of trading in the securities of Nanoveu Limited will be lifted immediately following the release by NVU of an announcement regarding a new product.

Nanoveu to incorporate antiviral nanotechnology into smartphone and tablet protective screens and cases, targeting late Q2 / early Q3 2020 product availability. Initial testing on the top layer of Nanoveu's planned products has demonstrated Nanoveu's technology to be effective against viruses and bacteria "“ including influenza A (subtype H3N2) and E. coli. Independent laboratories in the USA and Singapore have been engaged to conduct testing on prototypes for the human coronavirus OC43 (HCoV-OC43) (a betacoronavirus), which is the same genus as SARS-CoV-2 (the virus that causes COVID-19). Procurement for the first production run of smartphone protective screens is underway. Nanoveu's antiviral nanotechnology is considerably improved upon compared to existing anti-bacterial smartphone protective screens and cases which do not protect against viruses. Nanoveu is investigating pathways to market with potential for pre-orders in parallel with product development and production, targeting products being available in late Q2 2020 / early Q3 2020.

The securities of Nanoveu Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of NVU, pending the release of an announcement regarding a new product..

listed entity carried for record purposes only